Cambridge Investment Research Advisors, Inc. Summit Therapeutics Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 30,820 shares of SMMT stock, worth $576,642. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,820Holding current value
$576,642% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.8MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$631 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$162 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$75.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$73.1 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...